Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department.
Farkowski MM, Maciąg A, Żurawska M, Pytkowski M, Kowalik I, Woźniak J, Sterliński M, Szwed H. Farkowski MM, et al. Pol Arch Med Wewn. 2016 Jun 24;126(6):381-7. doi: 10.20452/pamw.3452. Epub 2016 Jun 24. Pol Arch Med Wewn. 2016. PMID: 27362390 Free article.
Efficacy and safety of antazoline for cardioversion of atrial fibrillation: propensity score matching analysis of a multicenter registry (CANT II Study).
Wybraniec MT, Maciąg A, Miśkowiec D, Ceynowa-Sielawko B, Balsam P, Wójcik M, Wróbel W, Farkowski M, Ćwiek-Rębowska E, Szołkiewicz M, Ozierański K, Błaszczyk R, Bula K, Dembowski T, Peller M, Krzowski B, Wańha W, Koziński M, Kasprzak JD, Szwed H, Mizia-Stec K. Wybraniec MT, et al. Pol Arch Intern Med. 2022 Jun 29;132(6):16234. doi: 10.20452/pamw.16234. Epub 2022 Mar 16. Pol Arch Intern Med. 2022. PMID: 35293200 Free article.
Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).
Farkowski MM, Maciag A, Kowalik I, Konka M, Szwed H, Pytkowski M. Farkowski MM, et al. Br J Clin Pharmacol. 2019 Jul;85(7):1552-1558. doi: 10.1111/bcp.13940. Epub 2019 May 23. Br J Clin Pharmacol. 2019. PMID: 30920001 Free PMC article.
Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.
Ceynowa-Sielawko B, Wybraniec MT, Topp-Zielińska A, Maciąg A, Miśkowiec D, Balsam P, Wójcik M, Wróbel W, Farkowski MM, Ćwiek-Rębowska E, Ozierański K, Błaszczyk R, Bula K, Dembowski T, Peller M, Krzowski B, Wańha W, Koziński M, Kasprzak JD, Szwed H, Mizia-Stec K, Szołkiewicz M. Ceynowa-Sielawko B, et al. Among authors: farkowski mm. Int J Environ Res Public Health. 2022 Apr 17;19(8):4880. doi: 10.3390/ijerph19084880. Int J Environ Res Public Health. 2022. PMID: 35457747 Free PMC article.
Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial.
Ciszewski J, Maciag A, Kowalik I, Syska P, Lewandowski M, Farkowski MM, Borowiec A, Chwyczko T, Pytkowski M, Szwed H, Sterlinski M. Ciszewski J, et al. Among authors: farkowski mm. Trials. 2014 Oct 4;15:386. doi: 10.1186/1745-6215-15-386. Trials. 2014. PMID: 25281275 Free PMC article. Clinical Trial.
69 results